U.S. markets close in 3 hours 1 minute

SPDR S&P Biotech ETF (XBI)

NYSEArca - Nasdaq Real Time Price. Currency in USD
Add to watchlist
126.62+1.52 (+1.22%)
As of 12:59PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous Close125.10
Open123.54
Bid126.04 x 1400
Ask126.06 x 1000
Day's Range123.23 - 127.46
52 Week Range97.15 - 174.79
Volume5,596,978
Avg. Volume7,602,263
Net Assets7.54B
NAV125.18
PE Ratio (TTM)N/A
Yield0.24%
YTD Daily Total Return-11.08%
Beta (5Y Monthly)1.22
Expense Ratio (net)0.35%
Inception Date2006-01-31
  • Yahoo Finance Video

    Biotech is ‘the superhero of the pandemic’: investor

    Antoine Papiernik, managing partner at Sofinnova Partners, joins Yahoo Finance to discuss trends in biotech and impacts the pandemic had on scientific discoveries.

  • ETF.com

    Spiking Yields Pierce Bonds & Growth Stocks

    Interest rates hit their highest levels in a year on Wednesday, putting pressure on long-duration assets.

  • MarketWatch

    Bluebird Bio shares slide 34% after company suspends trials of sickle cell disease treatment

    Shares of Bluebird Bio Inc. slid 34% in premarket trade Tuesday, after the biotech said it is temporarily suspending Phase 1/2 and Phase 3 trials of its LentiGlobin gene therapy for sickle cell disease after a report of a suspected unexpected serious adverse reaction of acute myeloid leukemia. The patient involved was treated more than five years ago and has not been diagnosed with AML, the company said in a statement. "The company is investigating the cause of this patient's AML in order to determine if there is any relationship to the use of BB305 lentiviral vector in the manufacture of LentiGlobin gene therapy for SCD," said Bluebird. "In addition, a second SUSAR of myelodysplastic syndrome (MDS) in a patient from Group C of HGB-206 was reported last week to the company and is currently being investigated." The company said it will work with regulators to complete its investigation. Shares have fallen 49% in the last 12 months, while the SPDR S&P Biotech ETF has gained 69% and the S&P 500 has sgained 16%.